Health Trials

About this trial

The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:

What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.

Participants wil:

* take Vacscepa or a placebo twice a day for 6 months * Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests

Eligibility criteria

Qualifiers

Hospitalization with CAP (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum)

age > 18 years;

given informed consent.

Disqualifiers

history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix).

active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));

pregnancy (all women of child bearing potential will have a negative BHCG test;

breastfeeding;

Trial design

Treatments tested in this trial

  • Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
  • Placebo

Treatment groups

168 Participants
are divided into 2 treatment groups

Locations

1
University of Ottawa Heart InstituteK1Y 4W7, OttawaOntario, Canada

Sponsors and collaborators

Ottawa Heart Institute Research Corporation

Lead sponsor

Source ClinicalTrials.gov